Sara K. Borrelli
Sara Borrelli is a registered patent attorney who has spent over 20 years counseling clients on their intellectual property issues. She prepares and prosecutes patent applications in a number of fields, most notably biotechnology, organic and inorganic chemistry, medical devices, pharmaceuticals, diagnostics, and veterinary and medical sciences. Sara is also an experienced trademark attorney who regularly reviews and advises clients on trademark clearance issues, prepares and files domestic trademark applications, and manages wide-ranging international trademark portfolios. She has negotiated and drafted numerous intellectual property agreements across a wide range of industries and has substantial experience in both patent and trademark litigation as well.
Sara is pleased to represent clients ranging from individuals to start-ups to universities to multi-national corporations. Regardless of the size of the client or the nature of the intellectual property, Sara focuses on providing clear and efficient advice that is practical and easy to understand. She has fostered a love of science and technology that began in grade school and continued throughout her days in undergraduate research labs, and now she enjoys bridging the gap between science and law for all of her clients.
Sara’s areas of focus are:
- IP Litigation
- IP Transactional Matters
B.S., Genetics, summa cum laude, Texas A&M University College Station
J.D., University of New Hampshire School of Law
United States Court of Appeals for the Federal Circuit
United States Patent and Trademark Office
United States District Court for the Northern and Eastern Districts of Texas
United States District Court for the Eastern District of Michigan
“Best Lawyers in Dallas,” D Magazine, 2018, 2021-2022
- The Dallas Bar Association – Intellectual Property Law Section
- International Trademark Association (INTA)
- Texas Aggie Bar Association
- Dallas Children’s Theater, Board of Directors
November 17, 2022Newsletters
View Jackson Walker’s November 2022 Diversity & Inclusion Newsletter, Perspectives.
September 27, 2022Client Results
Novaria Group, a leading manufacturer of specialty hardware, components, and coatings for the aerospace and defense industries, recently completed its acquisition of STROCO Manufacturing, Inc. This deal marks the sixth acquisition Novaria has announced from December of 2021 through July of 2022, taking place after its successful acquisitions of FMi Chemical, Hohman Plating, Advanced Coating, Hydro Fitting, and GK Mechanical Systems.
August 1, 2022Newsletters
View Jackson Walker’s August 2022 Diversity & Inclusion Newsletter, Perspectives.
April 25, 2022Attorney News
Jackson Walker congratulates the 21 attorneys recognized among D Magazine’s list of the “Best Lawyers in Dallas” for 2022. For recognition in the list, Dallas attorneys must be nominated by their peers on the basis that they offer unmatched counsel in one of 40 categories.
October 5, 2021Newsletters
View Jackson Walker’s October 2021 Diversity & Inclusion Newsletter, Perspectives.
May 24, 2021Client Results
Before a series of new comic book adventures could be introduced to the world, budding entrepreneurs faced some legal questions. How should they set up their company? What about intellectual property rights? With these questions in mind, Chrystal Baeza turned to the team at Jackson Walker for help.
April 28, 2021Attorney News
Jackson Walker congratulates the 23 attorneys recognized among D Magazine’s list of the “Best Lawyers in Dallas” for 2021.
July 10, 2018Attorney News
Thirty-three Jackson Walker attorneys were recognized in the “Best Lawyers in Dallas 2018” list by D Magazine, one of the premier publications in the city of Dallas. To be recognized in the list, attorneys must be nominated by their peers on the basis that they offer unmatched counsel in one of 34 categories.
June 13, 2017Insights
By Sara Borrelli
Today’s unanimous ruling by the U.S. Supreme Court in Sandoz v. Amgen injects much-needed certainty into a difficult statute and streamlines the process for biosimilar products to enter the marketplace following FDA approval under the Biologics Price Competition and Innovation Act (BPCIA).